Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 8/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | RANBP1 | P43487 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666427 | 1.00 | XPO1 (0.36) | XPO1HDAC1HDAC6RANBP1KCNH2 | |
| SCHEMBL29666388 | 0.85 | — | — | |
| SCHEMBL23116712 | 0.85 | — | — | |
| SCHEMBL26326308 | 0.84 | XPO1 (0.36) | XPO1HDAC1HDAC6RANBP1KCNH2 | |
| SCHEMBL3848312 | 0.76 | CYP11B1 (0.38) | HDAC1HDAC6TSHRLMNANPSR1 | |
| SCHEMBL26326405 | 0.74 | CYP11B1 (0.33) | HDAC1HDAC6ADORA2AADORA1 | |
| SCHEMBL23133400 | 0.70 | XPO1 (0.49) | XPO1RANBP1KCNH2 | |
| SCHEMBL21588070 | 0.70 | XPO1 (0.53) | XPO1RANBP1KCNH2 | |
| SCHEMBL29666402 | 0.70 | XPO1 (0.53) | XPO1RANBP1KCNH2 | |
| SCHEMBL26326310 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| CN-115089586-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112566902-B | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-112566902-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | XPO1 2/4885HDAC1 614/4885HDAC6 386/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | XPO1 2/4885HDAC1 614/4885HDAC6 386/4885 |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | XPO1 2/4885HDAC1 614/4885HDAC6 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.